Payer Archetyping – Expanding Horizons

October 4, 2018 Danielle Twigg

The traditional pharmaceutical market model is being challenged by the emergence of middle-income countries with rapidly growing economies, healthcare coverage, and willingness-to-pay for medicines. Understanding how these emerging markets determine appropriate pricing and reimbursement for public healthcare coverage of new therapies will thus become increasingly important considerations for global product launches. This research aims to analyse pricing and reimbursement processes across a broad range of markets and archetype these into groups based on commonalities in key decision-drivers.

Authors: Campbell J, Roibu C, Ivanova H, Macaulay R, PAREXEL International, London, United Kingdom

To find out more about this poster you can register to download it here after the ISPOR event.

Previous Article
Pan-European HTA – Where We Have Been, Where We Are Going?
Pan-European HTA – Where We Have Been, Where We Are Going?

Next Article
Less Haste, More Speed? Do European Accelerated Authorisations Translate Into Early Reimbursement And Patient Access?
Less Haste, More Speed? Do European Accelerated Authorisations Translate Into Early Reimbursement And Patient Access?